Direct Healthcare Professional Communication (DHPC) on brivudine: potentially fatal toxicity of fluoropyrimidines if administered shortly before or at the same time with brivudine or used within 4 weeks after the end of treatment with brivudine
2020.05.12
Active substance: brivudine
The Marketing Authorisation Holder in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM) would like to inform you that fatalities can occur as a result of an interaction between brivudine and fluoropyrimidines (e.g. fluorouracil, capecitabine, tegafur, flucytosine). At least 4 weeks must be awaited after the end of brivudine treatment before starting treatment with a fluoropyrimidine.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN